(Reuters) – The European Union’s drug regulator said on Friday it had recommended against approving Biogen Inc’s Alzheimer’s drug, Aduhelm, dealing a blow to the U.S. drugmaker after a panel voted against the treatment last month.
The European Medicines Agency said results from main studies of the drug were “conflicting and did not show overall that Aduhelm was effective” at treating adults with early stage Alzheimer’s, adding Biogen can ask for a review within 15 days.
(Reporting by Pushkala Aripaka in Bengaluru; Editing by Anil D’Silva)
